Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Operating Expenses: 2017-2019

Historic Operating Expenses for Monopar Therapeutics (MNPR) over the last 3 years, with Dec 2019 value amounting to $1.2 million.

  • Monopar Therapeutics' Operating Expenses rose 32.23% to $1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was $4.3 million, marking a year-over-year increase of 36.88%. This contributed to the annual value of $4.3 million for FY2019, which is 29.80% up from last year.
  • As of Q4 2019, Monopar Therapeutics' Operating Expenses stood at $1.2 million, which was up 61.29% from $759,448 recorded in Q3 2019.
  • Monopar Therapeutics' Operating Expenses' 5-year high stood at $14.9 million during Q3 2017, with a 5-year trough of $373,839 in Q1 2017.
  • Its 3-year average for Operating Expenses is $2.0 million, with a median of $828,354 in 2018.
  • Over the last 5 years, Monopar Therapeutics' Operating Expenses had its largest YoY gain of 140.01% in 2018, and its largest YoY loss of 95.52% in 2018.
  • Monopar Therapeutics' Operating Expenses (Quarterly) stood at $736,800 in 2017, then climbed by 25.73% to $926,358 in 2018, then soared by 32.23% to $1.2 million in 2019.
  • Its Operating Expenses stands at $1.2 million for Q4 2019, versus $759,448 for Q3 2019 and $932,109 for Q2 2019.